NCT01765465

Effect of Rowachol on Prevention of Postcholecystectomy Syndrome

Effect of Rowachol on Prevention of Postcholecystectomy Syndrome After Laparoscopic Cholecystectomy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 138 (actual)
• Sponsor: DongGuk University · Academic / Other
• Sex: All
• Age: 18 Years – 84 Years
• Healthy volunteers: Not accepted

Summary

Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually manifested by the presence of abdominal symptoms following gallbladder removal. The pathogenesis of PCS has not been identified; therefore there is no consensus of medical treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from patients with cholesterol gallstones, and to promote biliary lipid secretion. The purpose of this study is to determine whether Rowachol is useful in the prevention of PCS and symptoms change after laparoscopic cholecystectomy

Conditions

• Postcholecystectomy Syndrome

Interventions

Type	Name	Description
DRUG	Rowachol
DRUG	Placebo

Timeline

• Start date: 2013-01-01
• Primary completion: 2014-05-01
• Completion: 2014-07-01
• First posted: 2013-01-10
• Last updated: 2014-11-21
• Results posted: 2014-11-21

Locations

2 sites across 1 country: South Korea